1
|
Huang WC, Cheng F, Chen CC, Kuo PH, Wang YJ, Yin SC, Tu CM, Wu MH, Wang WY, Chen SE. A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration. Transl Vis Sci Technol 2021; 10:23. [PMID: 34932116 PMCID: PMC8711013 DOI: 10.1167/tvst.10.14.23] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose Drug delivery to posterior ocular tissues via topical eye drop administration is arduous due to the unique anatomy and physiology of the eye. Therefore, treatments for posterior eye disease have to be administered via intravitreal injection or systemic route, both of which have their drawbacks. Herein, the objective of this work was to demonstrate that a specially designed eye drop formulation could effectively deliver small-molecule vascular endothelial growth factor (VEGF) inhibitor to posterior ocular tissues for antiangiogenic therapy. Methods The unique eye drop formulation, termed ITRI AXN eye drops, was obtained from self-assembly of (2-hydroxypropyl)-β-cyclodextrin with a VEGF tyrosine kinase inhibitor, a hydrophilic polymer, hypromellose, and a complex stabilizer, caffeine. In vivo ocular pharmacokinetics studies were performed with New Zealand White (NZW) rabbits and Non Human Primates (NHP). The antiangiogenesis effect was evaluated on the Long-Evans rat with laser-induced choroidal neovascularization and pigmented Dutch-Belted rabbits with VEGF-induced retinal neovascularization. Results The successful drug transport from ocular surface to posterior ocular cavity was indicated by a drug biodistribution pattern in pharmacokinetic studies. Excellent drug exposure in the choroid and retina with the concentrations of 900- and 750-fold greater than drug IC50 0.5 hours post the eye drop administration (drug level: 0.8%) was observed on the NHP study. The obtained formulation also demonstrated a comparable antiangiogenic outcome with the intravitreal injection of anti-VEGF antibody on rat and rabbit disease models. Conclusions Our eye drop formulation has demonstrated great promise in antiangiogenic therapy against retinal and choroidal neovascularization in animal models. The results suggest that the aim of this work can be successfully achieved by the novel eye drop formulation. Translational Relevance The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy.
Collapse
Affiliation(s)
- Wen-Chia Huang
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Felice Cheng
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Chia-Ching Chen
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Po-Hsien Kuo
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Yen-Jen Wang
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Shao-Chan Yin
- Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Chia-Mu Tu
- Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Ming-Hsi Wu
- Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Wen-Yu Wang
- Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| | - Sung-En Chen
- Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China
| |
Collapse
|